ATLAS-IT-05 was an open-label, single-arm study in patients with advanced melanoma accessible for injections (cutaneous, subcutaneous, lymph node, or intramuscular tumors) and who had either exhausted treatment options or were not eligible for, suitable for, or willing to undergo such treatments.
The study aimed to assess the safety and efficacy of LTX-315 in combination with the immune checkpoint inhibitor (ICI) pembrolizumab in patients with advanced melanoma. LTX-315 has been administered with pembrolizumab in a previous Phase I/II study, and there were clear indications that LTX-315 + pembrolizumab was a clinically active combination. Furthermore, the addition of LTX-315 to pembrolizumab dosing did not appear to increase the overall incidence or severity profile of toxicities. The present study documented the preliminary efficacy, clinical safety, and tolerability of LTX-315 in combination with pembrolizumab, in a dose and regimen that is considered to be safe. Patient population consisted of patients with stage III B, C, D and Stage IVm1a, m1b unresectable metastatic melanoma with ECOG performance status of 0 or 1, who had received an FDA-approved anti-PD/PD-L1 therapy and had progressed after prior anti-PD-1 or anti-PD-L1 therapy, alone or in combination with systemic therapy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
23
Phase A Pembrolizumab will be given as 200 mg IV infusion over 30 minutes on Days 1 and 22. Phase B Pembrolizumab will be given as 400 mg IV infusion over 30 minutes every 6 weeks starting at Day 43 (3 weeks after the last dose of pembrolizumab in Phase A) until discontinuation from the study or for a maximum of 24 months' total therapy, whichever comes first.
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Levine Cancer Institute - Atrium Health
Charlotte, North Carolina, United States
University of Pittsburgh Medical Center (UPMC) Hilman Cancer Center
Pittsburgh, Pennsylvania, United States
Objective Response Rate (ORR)
Objective response rate is defined as the proportion of patients who achieved partial response (PR) and/or complete response (CR) per local investigator assessment using RECIST version 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: Patients were followed throughout the treatment period of up to 24 months and then for an additional 90 days after the end of treatment.
Clinical Benefit Rate
Clinical benefit rate was defined as the proportion of patients who respond to treatment, estimated as the proportion of patients who achieve stable disease (SD), PR, or CR per local investigator assessment using RECIST version 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: Patients were followed throughout the treatment period of up to 24 months and then for an additional 90 days after the end of treatment.
Overall Survival (OS)
Overall survival was evaluated as time from baseline until death and was summarized descriptively.
Time frame: Patients were followed throughout the treatment period of up to 24 months and then for an additional 90 days after the end of treatment.
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Related to LTX-315
TEAEs considered related to LTX-315 by the investigator, by preferred term. TEAEs were events with start date after the start of the Treatment Period and up to 30/90 days (30 days if non SAE, 90 days if SAE) after the end of the Treatment Period. If the patient initiated a new anticancer therapy, then 30 days were used for SAEs. A treatment related TEAE was defined as a TEAE considered by the investigator as related to treatment or with missing relationship to treatment.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
MD Anderson Cancer Centre
Houston, Texas, United States
Centre Hospitalier Regional Universitaire De Lille
Lille, France
Gustave Roussy Cancer Campus
Paris, France
Hospital Lyon Sud
Pierre-Bénite, France
Akershus University Hospital
Lørenskog, Norway
Oslo University Hospital--Radiumhospitalet
Oslo, Norway
Clínica Universidad de Navarra
Pamplona, Spain
Time frame: Patients were followed throughout the treatment period of up to 24 months and then for an additional 90 days after the end of treatment.
Grade ≥3 Treatment Related TEAEs
Treatment related TEAEs that were Grade ≥3
Time frame: Patients were followed throughout the treatment period of up to 24 months and then for an additional 90 days after the end of treatment.
Pharmacokinetic Results: Cmax
Secondary PK endpoints of LTX 315 in plasma in 20 patients enrolled in the study: maximum concentration (Cmax)
Time frame: LTX-315 in plasma was measured at screening and pre-dosing on Days 1, 2, 3, 8, 22, 43, and at post dosing on Day 3 following the last injection at; 1, 5, 10 (±2 mins), 20, 30, 40, 50, 60, 90, 120 and 150 min (±10 mins).
Pharmacokinetic Results: AUCinf
Secondary PK endpoints of LTX 315 in plasma in 20 patients enrolled in the study: area under the concentration time curve from time 0 extrapolated to infinity (AUCinf)
Time frame: LTX-315 in plasma was measured at screening and pre-dosing on Days 1, 2, 3, 8, 22, 43, and at post dosing on Day 3 following the last injection at; 1, 5, 10 (±2 mins), 20, 30, 40, 50, 60, 90, 120 and 150 min (±10 mins).
Pharmacokinetic Results: t1/2
Additional secondary PK endpoints of LTX 315 in plasma in 20 patients enrolled in the study were half-life (t1/2)
Time frame: LTX-315 in plasma was measured at screening and pre-dosing on Days 1, 2, 3, 8, 22, 43, and at post dosing on Day 3 following the last injection at; 1, 5, 10 (±2 mins), 20, 30, 40, 50, 60, 90, 120 and 150 min (±10 mins).